GSK plc (LON:GSK) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of GSK plc (LON:GSK) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is GBX 1,862.50 ($25.36).

GSK has been the topic of a number of recent analyst reports. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Wednesday, April 30th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research note on Friday, March 28th.

GSK Stock Up 1.5%

GSK opened at GBX 1,545.94 ($21.05) on Friday. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The company’s 50-day moving average is GBX 1,408.26 and its 200 day moving average is GBX 1,408.36. GSK has a fifty-two week low of GBX 1,242.50 ($16.92) and a fifty-two week high of GBX 1,678.68 ($22.85). The firm has a market capitalization of £62.73 billion, a P/E ratio of 24.97, a PEG ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last released its quarterly earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.61) earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Research analysts expect that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Buying and Selling at GSK

In other GSK news, insider Wendy Becker acquired 536 shares of the stock in a transaction dated Thursday, March 20th. The stock was purchased at an average cost of GBX 1,515 ($20.63) per share, for a total transaction of £8,120.40 ($11,055.68). Also, insider Emma Walmsley sold 5,473 shares of the business’s stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of GBX 1,449 ($19.73), for a total transaction of £79,303.77 ($107,969.73). 1.61% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.